Cervomed Inc. (CRVO) — SEC Filings
Cervomed Inc. (CRVO) — 50 SEC filings. Latest: 8-K (Dec 5, 2025). Includes 36 8-K, 6 10-Q, 2 DEF 14A.
View Cervomed Inc. on SEC EDGAR
Overview
Cervomed Inc. (CRVO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: CervoMed Inc. filed an 8-K on December 5, 2025, reporting on events that occurred on December 1, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., is incorpora
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant filing sentiment for Cervomed Inc. is neutral.
Filing Type Overview
Cervomed Inc. (CRVO) has filed 36 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 S-1/A, 1 S-1 with the SEC between Mar 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CRVO's 46 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 29 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3,997,784 |
| Net Income | -$18,879,077 |
| EPS | -$2.10 |
| Debt-to-Equity | N/A |
| Cash Position | $9,437,400 |
| Operating Margin | -512.5% |
| Total Assets | $30,610,778 |
| Total Debt | N/A |
Key Executives
- John Alam, M.D.
Industry Context
CervoMed operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry focused on developing novel therapies. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on clinical trial outcomes, intellectual property protection, and the ability to secure substantial funding for research and commercialization.
Top Tags
8-K (14) · financial-reporting (10) · financials (8) · filing (7) · 8-k (5) · company-update (5) · corporate-filing (5) · 10-Q (4) · pharmaceuticals (4) · sec-filing (4)
Executive Compensation
From the most recent DEF 14A filing (Apr 29, 2024):
- John Alam, M.D. — President & Chief Executive Officer
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $18.88M | Increased 97% for the nine months ended September 30, 2025, compared to $9.58M in 2024. |
| Research and Development Expenses | $15.99M | Increased 36.5% for the nine months ended September 30, 2025, from $11.71M in 2024. |
| Grant Revenue | $3.99M | Decreased 47.2% for the nine months ended September 30, 2025, from $7.58M in 2024. |
| Cash and Cash Equivalents | $9.44M | As of September 30, 2025, a slight increase from $8.99M at December 31, 2024. |
| Total Stockholders' Equity | $26.01M | Decreased from $39.20M at December 31, 2024, to September 30, 2025. |
| Common Shares Outstanding | 9,252,719 | As of November 5, 2025, reflecting recent share issuances. |
| Gross Proceeds from 2024 Private Placement | $149.4M | Completed on April 1, 2024, providing capital for operations. |
| Shares of Common Stock Sold | 550,000 | Resulting in $4,588,687 net proceeds during the nine months ended September 30, 2025. |
| Filing Date | 20251022 | The date the 8-K was filed. |
| Fiscal Year End | 1231 | Indicates the end of the company's fiscal year. |
| Revenue | $0 | for Q2 2025 and H1 2025, indicating pre-commercial stage |
| Research and Development Expense | $1,000 | for Q2 2025, a 90% decrease from Q2 2024 |
| General and Administrative Expense | $10,000 | for Q2 2025, a 90% decrease from Q2 2024 |
| Decrease in R&D and G&A expenses | 90% | reflects significant cost-cutting measures |
| Commission File Number | 001-37942 | Identifies the company's SEC filing history. |
Frequently Asked Questions
What are the latest SEC filings for Cervomed Inc. (CRVO)?
Cervomed Inc. has 50 recent SEC filings from Mar 2024 to Dec 2025, including 36 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CRVO filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Cervomed Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cervomed Inc. (CRVO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cervomed Inc.?
Key financial highlights from Cervomed Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CRVO?
The investment thesis for CRVO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cervomed Inc.?
Key executives identified across Cervomed Inc.'s filings include John Alam, M.D..
What are the main risk factors for Cervomed Inc. stock?
Of CRVO's 46 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 29 low-risk.
What are recent predictions and forward guidance from Cervomed Inc.?
Forward guidance and predictions for Cervomed Inc. are extracted from SEC filings as they are enriched.